Publication: Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
No Thumbnail Available
Identifiers
Date
2017-10-24
Authors
Moreso, Francesc
Crespo, Marta
Ruiz, Juan C
Torres, Armando
Gutierrez-Dalmau, Alex
Osuna, Antonio
Perelló, Manel
Pascual, Julio
Torres, Irina B
Redondo-Pachón, Dolores
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
There are no approved treatments for chronic antibody mediated rejection (ABMR). We conducted a multicenter, prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate efficacy and safety of intravenous immunoglobulins (IVIG) combined with rituximab (RTX) (EudraCT 2010-023746-67). Patients with transplant glomerulopathy and anti-HLA donor-specific antibodies (DSA) were eligible. Patients with estimated glomerular filtration rate (eGFR)
Description
MeSH Terms
Adult
Allografts
Chronic Disease
Double-Blind Method
Female
Follow-Up Studies
Glomerular Filtration Rate
Graft Rejection
Graft Survival
HLA Antigens
Humans
Immunoglobulins, Intravenous
Immunologic Factors
Isoantibodies
Kidney Failure, Chronic
Kidney Function Tests
Kidney Transplantation
Male
Middle Aged
Postoperative Complications
Prognosis
Prospective Studies
Risk Factors
Rituximab
Tissue Donors
Allografts
Chronic Disease
Double-Blind Method
Female
Follow-Up Studies
Glomerular Filtration Rate
Graft Rejection
Graft Survival
HLA Antigens
Humans
Immunoglobulins, Intravenous
Immunologic Factors
Isoantibodies
Kidney Failure, Chronic
Kidney Function Tests
Kidney Transplantation
Male
Middle Aged
Postoperative Complications
Prognosis
Prospective Studies
Risk Factors
Rituximab
Tissue Donors
DeCS Terms
CIE Terms
Keywords
clinical research/practice, clinical trial, kidney (allograft) function/dysfunction, kidney transplantation/nephrology, pathology/histopathology, rejection: antibody-mediated (ABMR)